Phase 3 biotech developing radiopharmaceutical therapies for cancer.
Industry: Health Care
Latest Trade: $62.49 0.00 (0.0%)
First Day Return: +33.3%
Return from IPO: +247.2%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 08/24/2023 |
Offer Price | $18.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 17.3 |
Deal Size ($mm) | $311 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 09/14/2023 |
Offer Price | $18.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 17.3 |
Deal Size ($mm) | $311 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
J.P. Morgan |
Jefferies |
more |
Company Data | |
---|---|
Headquarters | San Diego, CA, United States |
Founded | 2020 |
Employees at IPO | 88 |
Website rayzebio.com |